ABIONYX Pharma: Availability of the Universal Registration Document for the year 2019
April 27 2020 - 11:45AM
Business Wire
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 -
ABNX - PEA PME eligible), a new generation biotech company
dedicated to the discovery and development of innovative therapies
for patients, announces that it has filed with the “Autorité des
Marchés Financiers” (AMF) its 2019 Universal Registration Document
for the year ended December 31, 2019, dated April 24, 2020.
ABIONYX Pharma's Universal Registration Document for the
financial year ending December 31, 2019, includes in
particular:
- The annual financial report for 2019, consisting of the
consolidated financial statements, the annual financial statements
and the related statutory auditors' reports;
- The management report ;
- The corporate governance report;
- A description of the share buyback program.
This document is available on the company's website
(www.abionyx.com) and on the AMF website (www.amf-France.org). It
is also available at the company's registered office, 33-43 avenue
Georges Pompidou - Building D, Balma, 31130
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to
the discovery and development of innovative therapies for patients.
The biotech assets inherited from CERENIS Therapeutics constitute a
rich portfolio of valuable programs for the treatment of
cardiovascular diseases and associated metabolic diseases as well
as a HDL targeted drug delivery platform in oncology, more
specifically in immuno-oncology and chemotherapy.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200427005555/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Apr 2024 to May 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From May 2023 to May 2024